1204305-00-9

Basic information

• Product Name: 2-bromo-4-(4-ethoxybenzoyl)benzoic acid methyl ester
• Synonyms: 2-bromo-4-(4-ethoxybenzoyl)benzoic acid methyl ester
• CAS NO: 1204305-00-9
• Molecular Weight: 363.208
• Mol File: 1204305-00-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-bromo-4-(4-ethoxybenzoyl)benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-4-(4-ethoxybenzoyl)benzoic acid methyl ester(1204305-00-9)
• EPA Substance Registry System: 2-bromo-4-(4-ethoxybenzoyl)benzoic acid methyl ester(1204305-00-9)

Safety Data

• Hazardous Substances Data: 1204305-00-9(Hazardous Substances Data)

Upstream product

• 60728-41-8 1-methyl-2-aminoterephthalate 
• 87808-49-9 2-bromo-4-methyl-benzoic acid methyl ester 
• 264272-63-1 2-bromo-1,4-benzenedicarboxylic acid,1-methyl ester 
• 103-73-1 Phenetole 
• 1204305-02-1 methyl 2-bromo-4-(chloro-carbonyl)-benzoate 

Downstream Products

• 957228-84-1 2-bromo-4-(4-ethoxybenzyl)benzenemethanol 
• 1427370-52-2 1-(allyloxymethyl)-2-bromo-4-(4-ethoxybenzyl)benzene 
• 1427370-53-3 (2S,3S,4R,5R,6R)-2-[2-(allyloxymethyl)-5-(4-ethoxybenzyl)phenyl]-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran 
• 1427370-54-4 4-(4-ethoxybenzyl)-2-[(2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl]benzenemethanol 
• 1427370-55-5 4-(4-ethoxybenzyl)-2-[(2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl]benzoic acid 
• 1427370-56-6 (2R,3S,4S,4aR,10bS)-9-(4-ethoxybenzyl)-3,4-dihydroxy-2-(hydroxymethyl)-3,4,4a,10b-tetrahydropyrano[3,2-c][2]benzopyran-6(2H)-one 

Relevant articles and documents

Pyrano[3,2-c]benzopyran-6(2h)-one derivatives and uses thereof

The present invention relates to new pyrano[3,2-c]benzopyran-6(2H)-one derivatives that act as SGLT2 inhibitors, which makes them promising candidates for the treatment of diabetes and other diseases and conditions mediated by SGLT2. These new drugs also exhibit platelet aggregation inhibitory activity which makes them promising candidates in the treatment and/or prevention of prothrombotic conditions. The invention also relates to the use of such pyrano[3,2-c]benzopyran-6(2H)-one derivatives in the treatment or prevention of the diabetes and other disorders and conditions mediated by SGLT2, as a single active ingredient or in combination with another antidiabetic agent or a drug for the treatment of hypertension, chronic heart failure or atherosclerosis, and pharmaceutical compositions comprising said new pyrano[3,2-c]benzopyran-6(2H)-one derivatives.

Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors

A series of novel O-spiroketal C-arylglucosides have been prepared and evaluated in cell-based functional assays for activity against human sodium-dependent glucose co-transporters 1 and 2 (SGLT1 and 2). The core spiro[isobenzofuran-1,2′-pyran] structure proved to be an effective scaffold for diversification and a number of compounds with single digit nanomolar potency and high selectivity have been synthesized. Compound 5a promoted glucosuria when administered in vivo in rats and produced a significant blood glucose reduction effect.